Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Ligon Discovery and Bayer ink small-molecule deal
November 2010
SHARING OPTIONS:

CAMBRIDGE, Mass.Ligon Discovery has partnered with Germany's Bayer Schering Pharma AG to apply its proprietary Small Molecule Microarray screening platform (SMM) to discover potential first-in-class drug candidates for new disease targets. According to Ligon, its intellectual property estate encompasses the chemistry and methods that enable the attachment of all chemical collections, allowing the company to screen with any existing drug library. Because hits from SMM are based on existing compound libraries, they may require less downstream optimization in the form of medicinal chemistry and may progress more rapidly to clinical success, Ligon says. Financial terms of the partnership were not released.  
 
"Ligon is excited to collaborate with a leading global pharmaceutical company to discover drugs for important diseases that have previously proven difficult to address," says Ligon's CEO, Christian Bailey. "Our partnership with Bayer Schering Pharma provides the opportunity to demonstrate the unique capabilities of SMM, particularly to screen challenging targets and identify unique starting points for drug development."  
 

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.